Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 141

Related Citations for PubMed (Select 19688691)

1.

Analysis of NQO1 polymorphisms and p53 protein expression in patients with hepatocellular carcinoma.

Chiu MM, Ko YJ, Tsou AP, Chau GY, Chau YP.

Histol Histopathol. 2009 Oct;24(10):1223-32.

PMID:
19688691
2.

No association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and risk of hepatocellular carcinoma development in Turkish subjects.

Akkiz H, Bayram S, Bekar A, Akgöllü E, Ülger Y, Kaya BY, Sandikçi M, Özdil B.

Asian Pac J Cancer Prev. 2010;11(4):1051-8.

3.

A functional NQO1 609C>T polymorphism and risk of hepatocellular carcinoma in a Chinese population.

Liu F, Luo L, Wei Y, Wang W, Li B, Yan L, Wen T.

Tumour Biol. 2013 Feb;34(1):47-53. doi: 10.1007/s13277-012-0509-x. Epub 2012 Sep 13.

PMID:
22972504
4.

Association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism with esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population.

Zhang J, Schulz WA, Li Y, Wang R, Zotz R, Wen D, Siegel D, Ross D, Gabbert HE, Sarbia M.

Carcinogenesis. 2003 May;24(5):905-9.

5.

Association between NAD(P)H: quinone oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract.

Sarbia M, Bitzer M, Siegel D, Ross D, Schulz WA, Zotz RB, Kiel S, Geddert H, Kandemir Y, Walter A, Willers R, Gabbert HE.

Int J Cancer. 2003 Nov 10;107(3):381-6.

PMID:
14506737
6.

Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1.

Siegel D, McGuinness SM, Winski SL, Ross D.

Pharmacogenetics. 1999 Feb;9(1):113-21. Erratum in: Pharmacogenetics 1999 Jun;9(3):419.

PMID:
10208650
7.

Hypermethylation of NAD(P)H: quinone oxidoreductase 1 (NQO1) gene in human hepatocellular carcinoma.

Tada M, Yokosuka O, Fukai K, Chiba T, Imazeki F, Tokuhisa T, Saisho H.

J Hepatol. 2005 Apr;42(4):511-9. Epub 2004 Dec 25.

PMID:
15763338
8.

Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase).

Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, Franklin WA, Ross D.

Br J Cancer. 1997;75(1):69-75.

9.

[Relationship between hepatocellular carcinoma and the interaction between NQO1 polymorphisms and environmental factors].

Tan SK, Qiu XQ, Tang GF, Wang WW, Liu S.

Zhonghua Gan Zang Bing Za Zhi. 2012 Nov;20(11):833-7. doi: 10.3760/cma.j.issn.1007-3418.2012.11.007. Chinese.

PMID:
23206302
10.

Investigation of NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism in prostate cancer.

Ergen HA, Gormus U, Narter F, Zeybek U, Bulgurcuoglu S, Isbir T.

Anticancer Res. 2007 Nov-Dec;27(6B):4107-10.

11.

The NQO1 C609T polymorphism and hepatocellular carcinoma risk.

Fan Y, Hu D, Feng B, Wang W.

Tumour Biol. 2014 Aug;35(8):7343-50. doi: 10.1007/s13277-014-1712-8. Epub 2014 Feb 16. Review.

PMID:
24532470
12.

Clinical significance of a NAD(P)H: quinone oxidoreductase 1 polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal hyperthermic chemotherapy with mitomycin C.

Fleming RA, Drees J, Loggie BW, Russell GB, Geisinger KR, Morris RT, Sachs D, McQuellon RP.

Pharmacogenetics. 2002 Jan;12(1):31-7.

PMID:
11773862
13.

The C609T inborn polymorphism in NAD(P)H:quinone oxidoreductase 1 is associated with susceptibility to multiple sclerosis and affects the risk of development of the primary progressive form of the disease.

Stavropoulou C, Zachaki S, Alexoudi A, Chatzi I, Georgakakos VN, Terzoudi GI, Pantelias GE, Karageorgiou CE, Sambani C.

Free Radic Biol Med. 2011 Aug 1;51(3):713-8. doi: 10.1016/j.freeradbiomed.2011.04.043. Epub 2011 May 5.

PMID:
21605663
14.

Clinical significance of NQO1 C609T polymorphisms after postoperative radiation therapy in completely resected non-small cell lung cancer.

Song SY, Jeong SY, Park HJ, Park SI, Kim DK, Kim YH, Shin SS, Lee SW, Ahn SD, Kim JH, Lee JS, Choi EK.

Lung Cancer. 2010 May;68(2):278-82. doi: 10.1016/j.lungcan.2009.06.009.

PMID:
19596483
15.

NAD(P)H:quinone oxidoreductase 1 null genotype is not associated with pediatric de novo acute leukemia.

Sirma S, Agaoglu L, Yildiz I, Cayli D, Horgusluoglu E, Anak S, Yuksel L, Unuvar A, Celkan T, Apak H, Karakas Z, Devecioglu O, Ozbek U.

Pediatr Blood Cancer. 2004 Oct;43(5):568-70.

PMID:
15382274
16.

C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.

Takakuwa O, Oguri T, Ozasa H, Uemura T, Kunii E, Kasai D, Miyazaki M, Maeno K, Sato S.

J Thorac Oncol. 2011 Nov;6(11):1826-32. doi: 10.1097/JTO.0b013e318229137d.

PMID:
21964527
17.

NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors.

Lafuente MJ, Casterad X, Trias M, Ascaso C, Molina R, Ballesta A, Zheng S, Wiencke JK, Lafuente A.

Carcinogenesis. 2000 Oct;21(10):1813-9.

18.

[The NAD(P)H: quinone oxidoreductase 1 C609T polymorphism and susceptibility to esophageal cancer].

Zhang JH, Li Y, Wang R, Sarbia M, Guo W, Wen DG, Wei LZ, Chen ZF, Kuang G, Zhang LW, He M, Wu ML, Wang SJ.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2003 Dec;20(6):544-6. Chinese.

PMID:
14669229
19.

Increased levels of NAD(P)H: quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: A potential biomarker of early damage in the pancreas.

Lyn-Cook BD, Yan-Sanders Y, Moore S, Taylor S, Word B, Hammons GJ.

Cell Biol Toxicol. 2006 Mar;22(2):73-80. Epub 2006 Mar 9.

PMID:
16532285
20.

Association between mitochondrial DNA 4,977 bp deletion and NAD(P)H:quinone oxidoreductase 1 C609T polymorphism in human breast tissues.

Tseng LM, Yin PH, Tsai YF, Chi CW, Wu CW, Lee LM, Lee HC.

Oncol Rep. 2009 May;21(5):1169-74.

PMID:
19360290
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk